-- Clinical trial results with chemokine receptor CCR2 inhibitor CCX140 in diabetic nephropathy selected for Late Breaking Clinical Trial Oral Presentation --
-- Separately, poster presentation of anti-thrombogenic potential of complement C5a receptor inhibitor CCX168 in serum from patients with aHUS --
MOUNTAIN VIEW, Calif., May 26, 2015 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today announced that data from its Phase II clinical trial in diabetic nephropathy with CCX140, an inhibitor of the chemokine receptor known as CCR2, has been selected for an oral presentation in the Late Breaking Clinical Trial session at the 52nd Annual European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress being held May 28 to 31 in London, UK.
The Company's CCX140 Phase II clinical trial was conducted at multiple study centers across six European countries and enrolled patients with diabetic nephropathy for a 52-week treatment period. The primary efficacy endpoint, which was met successfully in the trial, was the evaluation of the effect of CCX140 treatment over 52 weeks on first morning urinary albumin:creatinine ratio. CCX140 appeared to be well tolerated with no safety issues being observed that would prevent further clinical development of CCX140 in diabetic nephropathy.
CCX140 Late Breaking Oral Presentation
|Title:||CCR2 Inhibitor CCX140 Effective in Phase 2 Clinical Trial in Diabetic Nephropathy|
|Presenter:||Prof. Dick de Zeeuw, M.D., Ph.D., in the Department of Clinical Pharmacy and Pharmacology at the University Medical Center in Groningen, The Netherlands.|
|Symposium:||Late Breaking Clinical Trials|
|Date:||Friday, May 29, 2015, 12:00 p.m. GMT|
In addition, the Company will present proof of concept data that supports the initiation of a clinical trial in atypical hemolytic uremic syndrome (aHUS) with CCX168, the Company's potent, orally available, highly specific small molecule inhibitor of the complement C5a receptor, or C5aR. The poster presentation will outline the anti-thrombogenic potential effect of CCX168 in serum from patients with aHUS.
CCX168 Poster Presentation
|Title:||Inhibition of the C5a Receptor by CCX168 Markedly Reduces the Thrombogenic Potential of Serum from Patients with atypical Hemolytic Uremic Syndrome (Poster number SP004)|
|Date:||Saturday, May 30, 2015 (9:30 – 10:45 a.m. GMT)|
CCX140 is an inhibitor of the chemokine receptor known as CCR2. CCR2 is found on subsets of monocytes and macrophages, which are cells of the immune system believed to play an important role in inflammatory processes. Blocking CCR2 is intended to reduce the abnormal monocyte- and macrophage-driven inflammatory response implicated in renal diseases such as diabetic nephropathy. CCR2 may also have a direct role in the function of other specialized cells in the kidney, where its inhibition would correlate with a positive therapeutic effect.
CCX168 is a potent, orally available and highly specific small molecule inhibitor of the C5a receptor. In addition to initiating a Phase II aHUS trial in 2015, ChemoCentryx has ongoing CCX168 Phase II clinical trials in North America and Europe for the treatment of anti-neutrophil cytoplasmic antibody (ANCA), associated vasculitis, or AAV. The U.S. Food and Drug Administration has granted orphan-drug designation for CCX168 for the treatment of patients with AAV, (which includes Wegener's granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome) and also for the treatment of patients with aHUS. The European Commission has granted orphan medicinal product designation for CCX168 for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis). Both conditions are forms of ANCA-associated vasculitis (AAV). A proof of concept clinical trial in IgA nephropathy was also initiated in 2015.
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. CCX140, a CCR2 inhibitor, successfully completed a Phase II clinical trial where it was shown to be safe and well tolerated while demonstrating statistically significant improvements in kidney function in patients with diabetic nephropathy. CCX168, a C5aR inhibitor, is in Phase II development for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). CCX168 appears to be safe, well tolerated and successful in allowing both reduction and elimination of high-dose corticosteroids, part of standard of care for AAV patients, without compromising efficacy or safety during a 12-week treatment period. CCX872, a second CCR2 inhibitor, successfully completed Phase I development and is in clinical development for the treatment of non-resectable pancreatic cancer. Vercirnon (also known as Traficet-EN or CCX282) is a specific CCR9 inhibitor for the treatment of inflammatory bowel disease. Other clinical programs include CCX507, a next generation CCR9 inhibitor, which has successfully completed Phase I development and CCX354, a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis. ChemoCentryx also has several programs in advanced preclinical development.
ChemoCentryx cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential" or "continue" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the ChemoCentryx business and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"). Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ChemoCentryx's periodic reports filed with the SEC, including ChemoCentryx's Annual Report on Form 10-K filed with the SEC March 13, 2015 and its other reports which are available from the SEC's website (www.sec.gov) and on ChemoCentryx's website (www.chemocentryx.com) under the heading "Investors." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Source: ChemoCentryx (CCXI-G)
CONTACT: Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer or Markus J. Cappel, Ph.D. Chief Business Officer 650.210.2900 firstname.lastname@example.org Media: Denise Powell 510.703.9491 email@example.com Investors: Kimberly Minarovich Burns McClellan 212.213.0006 firstname.lastname@example.org